GPEC receives unrestricted grant of $250,000 to study new treatments for breast cancer

December 27, 2015

Another GPEC project concerns a little understood and difficult to treat tumour of the ovary. After having helped decode ovarian cancers with state-of-the-art genome sequencing technologies, in collaboration with the BC Cancer Agency's Genome Sciences Centre, they identified a recurring mutation in granulosa-cell tumours of the ovary, and GPEC is now working on new diagnostics and treatments for this cancer.

With the work already accomplished and the many projects ahead, the centre is well-positioned to play a critical role in translating fundamental research into clinic practice.

"Sanofi-aventis believes that research into personalized medicine is a great way to deliver value to the Canadian healthcare system," said Hugh O'Neill, President and CEO of sanofi-aventis Canada. "By identifying the appropriate and inappropriate patients for various treatments, organizations like GPEC are reducing costs for the Canadian healthcare system and realizing the true value of innovative medicines."

Source: VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE